Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-015"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-015"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0162
lpv:speaker	lp:Alessandro Foglietta2
lpv:spokenAs	member; ENVI (2007-01-31--2009-07-13)3 treasurer; UEN (2004-11-14--2009-07-13)3 substitute; Delegation for relations with Canada (2007-03-14--2009-07-13)3 member; Delegation to the EU-Chile Joint Parliamentary Committee (2004-09-15--2009-07-13)3 substitute; CULT (2007-01-31--2009-07-13)3 unknown; Alleanza nazionale (2004-07-20--2009-07-13)3 member; Temporary Committee on Climate Change (2007-05-10--2009-02-04)3
lpv:translated text	"Mr President, ladies and gentlemen, I would like to express my support for this report, which is perfectly in line with the commitment to better regulation that Europe has stood for for many years. The new system of marketing authorisations for medicinal products will considerably simplify the procedure in the case of minor changes or new scientific discoveries and will signify a substantial easing of the technical and administrative burden on businesses. All of this is fully in keeping with the goals set out in the Lisbon strategy launched by the European institutions at the dawn of the new millennium. It identifies better regulation as one of the pillars underpinning the growth of the economy and jobs in Europe. It cannot be denied that the competitiveness of our businesses is suffering under the excessive legislative and bureaucratic conditions on manufacturing that have accumulated in recent decades, and that the impact of this is becoming ever more burdensome and unsustainable in the case of small and medium-sized enterprises that form the backbone of the national production system in many Member States. More to the point, at this precise moment in time, when the international crisis is threatening to suffocate our economy, we cannot allow ourselves to put our businesses at a further disadvantage with wasted costs and administrative delays. The will to streamline the legislative framework must be perceived as a duty and an unbreakable commitment. I am pleased that the Council, too, has accepted the European Parliament’s request to protect small and medium-sized enterprises by excluding from the scope authorisations for pharmaceuticals issued by Member States up to 1998. This has prevented small and medium-sized enterprises from having to make further efforts in order to comply with current legislation."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph